| |
著者: Mariko Kobayashi, Fumitaka Suzuki, Norio Akuta, Hiromi Yatsuji, Tetsuya Hosaka, Hitomi Sezaki, Masahiro Kobayashi, Yusuke Kawamura, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Rie Mineta, Satomi Iwasaki, Sachiyo Watahiki, Hiromitsu Kumada
雑誌名: Hepatol Res. 2010 Feb;40(2):125-34. doi: 10.1111/j.1872-034X.2009.00565.x. Epub 2009 Sep 25.
Abstract/Text
Aim: Continuous lamivudine treatment is associated with high frequency of drug resistance. We analyzed the incidence of tyrosine-methionine-aspartate-aspartate (YMDD) motif mutant and breakthrough hepatitis (BTH) in hepatitis B virus (HBV) DNA positive patients receiving lamivudine for > 1 year and correlated it with HBV DNA and alanine aminotransferase (ALT) levels to evaluate if these measurements can provide a practical option for monitoring patients in clinical practice and define early switch from lamivudine therapy. Methods: Of the 929 patients receiving lamivudine for > 1 year, 359 patients who maintained an ALT level of /= 3 years. Results: The incidence of YMDD motif in patients receiving lamivudine for < 3 years was 27% in patients with ALT
PMID 19788696 Hepatol Res. 2010 Feb;40(2):125-34. doi: 10.1111/j.1872-034X.2009.00565.x. Epub 2009 Sep 25.
|
